HOME>Investor Relations

Investor Relations

Share Price Information

IR Calendar

2017
May 10
Announcement of FY2016 Financial Results
February 6
Announcement of FY2016 3rd Quater Financial Results

What's New

  • RSS
  • About RSS

News Release List

2017
May 23 Topics Notice of Convocation of the 10th Ordinary General Meeting of Shareholders NEW
May 18 Release Approval for partial change in administration / dosage for Crohn’s disease for REMICADE for I.V. Infusion 100, an anti-human TNFα monoclonal antibodyPDF
May 16 Release Mitsubishi Tanabe Pharma announces The Lancet Neurology publication of the positive clinical results of Edaravone for ALSPDF
May 11 Topics IR Meeting for FY2016 Business Results[Material][Video]
May 10 Release Differences Between Non-Consolidated Actual Results for FY2015 and FY2016PDF
May 10 Release Announcement of Financial Results for FY2016
⇒R&D Pipeline "State of New Product Development"
May 10 Release Notice of Dividend of Retained EarningsPDF
May 10 Release Notice Regarding Revision of Business Structure for Recombinant Human Serum Albumin PreparationPDF
May 9 Release Establishment of Vaccine Manufacturing Joint Venture: BIKEN CO.,Ltd.PDF
May 8 Release New Japan-originated ALS treatment option available to patients in the U.S. ―U.S. FDA approves RADICAVA (edaravone) for the treatment of ALSPDF
April 26 Release Introduction of Performance-Linked Stock Compensation Plan for Board DirectorsPDF
April 24 Release Mitsubishi Tanabe Pharma Group receives import and marketing permission in Taiwan for CANAGLU Tablets 100mg, a treatment agent for type 2 diabetes mellitusPDF
March 30 Release Notice regarding approval of indication of ulcerative colitis and additional formulation for SIMPONI subcutaneous injection 50mg syringe (generic name: golimumab), a human monoclonal antibody specific for human TNF αPDF
March 29 Release Mitsubishi Tanabe Pharma and Daiichi Sankyo to Expand Strategic Alliance in the Diabetes Field The companies enter into a marketing alliance agreement for MT-2412, a combination drug for the treatment of type 2 diabetes mellitus, following co-operation for TENELIA Tablets, a selective DPP-4 inhibitor, and CANAGLU Tablets, an SGLT2 inhibitorPDF
March 28 Release Split off and transfer of Generic Drugs and Part of Long-Listed Products Business and Change of SubsidiaryPDF
February 6 Release Announcement of FY2016 3rd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
February 6 Topics IR Meeting for FY2016 3rd Quarter Business Results[Material][Audio]
February 3 Release Mitsubishi Tanabe Pharma Corporation Strategically Strengthens Its Foundation in the Field of Inflammatory Bowel Disease Mitsubishi Tanabe Pharma signs co-promotion agreement with Janssen Pharmaceutical K.K. for STELARA for an indication of Crohn’s diseasePDF
January 27 Release Biogen and Mitsubishi Tanabe Pharma Terminate the License Agreement on MT-1303PDF
2016
December 9 Topics 12-month Edaravone Clinical Study Data in ALS Presented at the 27th International Symposium on ALS/MNDPDF
December 7 Topics Business Briefing [Material][Video]
November 7 Release Basic Agreement on the Establishment of a Joint VenturePDF
November 1 Release Announcement of FY2016 2nd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
November 1 Topics IR Meeting for FY2016 2nd Quarter Business Results[Material][Audio]
November 1 Release Mitsubishi Tanabe Pharma Takes on the Challenge of Cell Therapy with the Conclusion of an Invossa Licensing Agreement with Kolon Life Science Aiming for therapy that addresses unmet medical needs in the treatment of knee osteoarthritisPDF
October 25 Release Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2017PDF
October 5 Topics CSR Activities Report 2016
October 5 Release Joint research identifies hit compounds for the development of a new treatment for malaria Mitsubishi Tanabe Pharma uses its compound library in joint research activities with Medicines for Malaria Venture ―Targeting treatments for infectious diseases that burden the developing world―PDF
October 4 Release Execution of Basic Agreement for Sales Anti-Allergy Agent, Rupatadine TabletsPDF
September 6 Release Application for partial change in administration/dosage for Crohn's disease for REMICADE for I.V. Infusion 100, an anti-human TNFα monoclonal antibodyPDF
August 30 Release FDA Accepts Mitsubishi Tanabe Pharma’s NDA Filing for Edaravone to Treat ALSPDF
August 30 Topics Mitsubishi Tanabe Pharma Corporate Report 2016
August 26 Release Valixa Tablet 450mg Approval for Additional Indication in Japan for the Prevention of CMV disease in organ transplant patientsPDF
August 23 Release Application filed in Japan fortype 2 diabetes mellitus treatment agent combination drug - Combination of selective DPP-4 inhibitor TENELIA Tablets and SGLT2 inhibitor CANAGLU Tablets -PDF
August 2 Release Announcement of FY2016 1st Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
August 2 Topics IR Meeting for FY2016 1st Quarter Business Results[Material][Audio]
June 23 Topics Corporate Governance ReportPDF
June 22 Release Regarding Nomination Committee and Compensation CommitteePDF
June 22 Topics Notice of Resolution of the 9th Ordinary General Meeting of Shareholders
⇒Results of the Exercise of Voting Rights(June 23, 2016)
June 20 Release Mitsubishi Tanabe Pharma Submits New Drug Application for Edaravone to Treat ALS in the United StatesPDF
June 6 Release Mitsubishi Tanabe Pharma contribute funding to Global Health Innovative Technology FundPDF
May 20 Topics Notice of Convocation of the 9th Ordinary General Meeting of Shareholders
May 13 Release Approval of REMICADE for I.V. Infusion 100, an Anti-Human TNFα Monoclonal Antibody, for a Partial Change in Dosage and Usage in PsoriasisPDF
May 13 Release Corrections with respect to “Summary of Financial Results for year ended March 31, 2016” (Japan GAAP) (Consolidated)PDF
May 12 Topics IR Meeting for FY2015 Business Results[Material][Audio]
May 11 Release Announcement of Financial Results for FY2015
⇒R&D Pipeline "State of New Product Development"
May 11 Release Notice of Dividend of Retained EarningsPDF
April 27 Release Change of Representative Director, Director and Corporate AuditorPDF
April 20 Topics Mitsubishi Tanabe Pharma Corporation Presents Edaravone Clinical Trial Data in ALS at 2016 American Academy of Neurology Annual MeetingPDF
March 29 Release Astellas and Mitsubishi Tanabe Pharma Execute Agreement for Share of Compound LibrariesPDF
March 22 Release Valixa Tablet 450 mg Application for Additional Indication in Japan for the Prevention of CMV disease in organ transplant patients Public Knowledge-based ApplicationPDF
March 15 Topics Corporate Governance ReportPDF
March 10 Release Notice regarding change of current commercialization scheme to new strategic co-promotion partnership in Japan for RA treatment agent Simponi subcutaneous injection 50 mg syringe (generic name: golimumab)PDF
February 23 Release Mitsubishi Tanabe Pharma Enhances Operations in the United StatesPDF
February 3 Release Announcement of FY2015 3rd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
February 3 Topics IR Meeting for FY2015 3rd Quarter Business Results[Material][Audio]
⇒[Q&A](February 9, 2016)
February 3 Release Notice Regarding Results of Early Retirement ProgramPDF

Investor Relations

Share Price Information

ReadSpeaker docReader makes documents accessible to all users including users with vision problems letting users view and listen to texts.
User guide